Abstract
As a practicing clinician, diseases affecting the optic nerve are most frequently seen by manifesting in unilateral blurred vision or loss of vision. Fundoscopy is usually negative (this is the case when ‘neither the patient nor the doctor can see anything’). The possible underlying causes can include demyelination, compression, infiltrative process, inflammation, trauma or ischemia. A common feature of all of these conditions is that the optic nerve is injured behind the optic disc: within the intraorbital, the intracanalicular or intracranial space.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol. 2005;139:1101–8.
Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med. 2006;354:1273–80.
Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, Brown CH. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med. 1993;329:1764–9.
Beck RW, Trobe JD, Moke PS, Gal RL, Xing D, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, Corbett J, Eggenberger E, Goodwin JA, Katz B, Kaufman DI, Keltner JL, Kupersmith MJ, Miller NR, Nazarian S, Orengo-Nania S, Savino PJ, Shults WT, Smith CH, Wall M. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003;121:944–9.
Beck RW, Smith CH, Gal RL, Xing D, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, Corbett J, Eggenberger E, Goodwin JA, Katz B, Kaufman DI, Keltner JL, Kupersmith MJ, Miller NR, Moke PS, Nazarian S, Orengo-Nania S, Savino PJ, Shults WT, Trobe JD, Wall M. Neurologic impairment 10 years after optic neuritis. Arch Neurol. 2004a;61:1386–9.
Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, Corbett J, Eggenberger E, Goodwin JA, Katz B, Kaufman DI, Keltner JL, Kupersmith MJ, Miller NR, Moke PS, Nazarian S, Orengo-Nania S, Savino PJ, Shults WT, Smith CH, Trobe JD, Wall M, Xing D. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol. 2004b;137:77–83.
Cleary PA, Beck RW, Bourque LB, Backlund JC, Miskala PH. Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial. J Neuroophthalmol. 1997;17:18–23.
Cole SR, Beck RW, Moke PS, Gal RL, Long DT. The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Optic Neuritis Treatment Trial. Invest Ophthalmol Vis Sci. 2000;41:1017–21.
Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343:898–904.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den NS, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121–7.
The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. 1997. Neurology. 2001;57:S36–45.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Lovas, G. (2016). Retrobulbar Optic Neuropathy: From the Neurologist’s Approach. In: Somlai, J., Kovács, T. (eds) Neuro-Ophthalmology. Springer, Cham. https://doi.org/10.1007/978-3-319-28956-4_40
Download citation
DOI: https://doi.org/10.1007/978-3-319-28956-4_40
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-28954-0
Online ISBN: 978-3-319-28956-4
eBook Packages: MedicineMedicine (R0)